Erectile dysfunction drug fails for diastolic heart failure patients

Highly anticipated multicenter trial fails to confirm results of smaller studies

2013-03-12

(Press-News.org) SAN FRANCISCO (March 11, 2013) — Despite high expectations for a commonly used erectile dysfunction drug to treat patients with diastolic heart failure, no beneficial effects were found in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session.

The RELAX Study is the first multicenter trial to look at the effect of chronic therapy with sildenafil in diastolic heart failure. Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor, a class of drugs used to treat erectile dysfunction and certain types of pulmonary arterial hypertension. Positive results with sildenafil in smaller studies and animal models provided the impetus for the study. But, compared to the placebo, researchers found no beneficial effect of the drug on the primary endpoint of participants' maximum exercise capacity assessed by peak oxygen consumption nor on secondary endpoints of submaximal exercise capacity (as tested by how far patients could walk in six minutes), clinical status, or cardiovascular structure and function.

"The results of our study were surprising and disappointing," said Margaret Redfield, MD, professor of medicine at the Mayo Clinic in Rochester, Minn., and the study's lead author. "There was a lot of anticipation around this study based on other research, and we were hoping to find something that would help these patients, as there are currently few options for treatment."

While current treatment for diastolic heart failure includes recommendations for weight loss, smoking cessation and controlling blood pressure, there are no medications available specifically for its treatment. Because sildenafil can increase blood supply to the lungs, and in animal studies it improved heart and vascular structure and function, researchers believed the drug would improve heart and lung function for diastolic heart failure patients.

According to Dr. Redfield, while it is possible that factors such as insufficient drug dosage or duration contributed to their results, she thinks this is unlikely based on the outcomes of other studies finding benefits from sildenafil.

It is more likely that, compared to other types of heart failure, the disease process seen in diastolic heart failure is different and does not respond well to this category of drug, she said.

Diastolic heart failure is a type of heart failure in which the heart's lower chambers (the ventricles) become stiff and cannot fully relax and fill between beats. When the heart cannot pump blood effectively, blood can back up into the lungs and the rest of the body, causing heart failure symptoms such as shortness of breath. In the RELAX study, patients with diastolic heart failure were enrolled in nine primary centers that make up the Heart Failure Clinical Research Network as well as 16 associated centers. To meet inclusion criteria, participants had to do a cardiopulmonary exercise test and have heart and blood tests showing that they had severe limitations in exercise capacity and abnormalities in the structure and function of their hearts.

The primary endpoint of the study was peak exercise capacity after 24 weeks of therapy with the drug sildenafil. This drug is more commonly known as Viagra and used to treat erectile dysfunction or as Revatio and used for treatment of pulmonary arterial hypertension. Other outcomes of the study included how far participants could walk in a six-minute exercise test, a clinical score based on patients' health outcomes and quality of life, and cardiovascular structure and function tests including echocardiographs, MRIs and biomarker data from blood tests.

The study was a double-blind, placebo-controlled, randomized clinical trial. For all outcomes, study results were neutral, showing no beneficial effect of sildenafil on heart failure patients. Although sildenafil and other PDE-5 inhibitors are not labeled for heart failure, it is possible that some clinicians may be prescribing these drugs for their heart failure patients based on the results of preliminary studies, which suggest a benefit.

"RELAX study results should discourage this practice, particularly considering the high cost of the drug," Dr. Redfield said.

While Dr. Redfield does not believe a larger trial of PDE-5 inhibitors is warranted in the general population of patients with diastolic heart failure, she said further research is needed to ascertain their potential benefits with certain subgroups of patients. Other small studies have demonstrated benefits from the drug for patients with diastolic heart failure who also had high blood pressure, right ventricular dysfunction and pulmonary arterial hypertension.

"Given these results, future studies should be done with this subset of patients," Dr. Redfield said, noting that ongoing trials in the U.S. and in Europe are assessing the effect of PDE-5 inhibitors in heart failure with reduced ejection fraction.

### The RELAX Study was funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health, which funds the Heart Failure Clinical Research Network, now in its seventh year.

This study will be simultaneously published in the Journal of the American Medical Association (JAMA) and will appear in the March 27 print edition and be released online at the time of presentation.

The ACC's Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC13 for the latest news from the meeting.

The American College of Cardiology is a nonprofit medical society comprised of 43,000 physicians, surgeons, nurses, physician assistants, pharmacists and practice managers. The College is dedicated to transforming cardiovascular care, improving heart health and advancing quality improvement, patient-centered care, payment innovation and professionalism. The ACC also leads the formulation of important cardiovascular health policy, standards and guidelines. It bestows credentials upon cardiovascular specialists, provides professional education, supports and disseminates cardiovascular research, and operates national registries to measure and promote quality care. For more information, visit cardiosource.org.

Dr. Redfield will be available to the media on Monday, March 11, at 12:15 p.m. in Moscone Center, South, Room 300.

Dr. Redfield will present the study "Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Trial" on Monday, March 11 at 11:30 a.m., in Moscone Center, South, Esplanade Ballroom.

ELSE PRESS RELEASES FROM THIS DATE:

Low T3 syndrome predicts unfavorable outcomes in surgical patients with brain tumor

2013-03-12

Charlottesville, VA (March 12, 2013). In a study of 90 patients undergoing surgery for brain tumor, researchers in Lithuania (Lithuanian University of Health Sciences) and the United States (University of North Carolina at Chapel Hill and Brigham & Women's Hospital, Harvard University) have discovered that the finding of low T3 (triiodothyronine) syndrome is predictive of unfavorable clinical outcomes and depressive symptoms. Details of this study are furnished in the article "Low triiodothyronine syndrome as a predictor of poor outcomes in patients undergoing brain tumor ...

What impact does a day of roller derby have on our skin microbiome?

2013-03-12

The human skin is home to countless microorganisms that we can't see, but these microbes help define who we are. Our invisible passengers – known as the skin microbiome - contribute to our health in numerous ways including educating our immune system, protecting us from pathogens, and mediating skin disorders. In a new study, researchers investigated how the skin microbiome is transmitted between players in a contact sport, using roller derby as their model system. The skin is the largest organ and an important barrier that regulates microbial entry into the human body. ...

Hereditary neurodegeneration linked to ADP-ribose modification

2013-03-12

HEIDELBERG, 12 March 2013 – Attaching chains of the small molecule ADP-ribose to proteins is important for a cell's survival and the repair of DNA damage, making this process a promising target for the development of new cancer drugs. Researchers have now identified a much sought after enzyme that removes such ADP-ribose modifications from proteins by studying a genetic mutation that causes neurodegenerative disease in humans. These findings, published today in The EMBO Journal, suggest that not only addition but also removal of ADP-ribose from proteins is essential for ...

Extremely rare triple quasar found

2013-03-12

Pasadena, CA—For only the second time in history, a team of scientists--including Carnegie's Michele Fumagalli--have discovered an extremely rare triple quasar system. Their work is published by Monthly Notices of the Royal Astronomical Society. It is available online. Quasars are extremely bright and powerful sources of energy that sit in the center of a galaxy, surrounding a black hole. In systems with multiple quasars, the bodies are held together by gravity and are believed to be the product of galaxies colliding. It is very difficult to observe triplet quasar ...

Stanford researchers map out an alternative energy future for New York

2013-03-12

New York Gov. Andrew Cuomo will soon decide whether to approve hydraulic fracturing for natural gas in the state. To date, no alternative to expanded gas drilling has been proposed. But a new study finds that it is technically and economically feasible to convert New York's all-purpose energy infrastructure to one powered by wind, water and sunlight (WWS). The plan, scheduled for publication in the journal Energy Policy, shows the way to a sustainable, inexpensive and reliable energy supply that creates local jobs and saves the state billions of dollars in pollution-related ...

Fluorescent light revealed as gauge of coral health

2013-03-12

Coral reefs not only provide the world with rich, productive ecosystems and photogenic undersea settings, they also contribute an economic boost valued at hundreds of billions of dollars. But their decline in recent years due to a variety of threats—from pollution to climate warming—has lent urgency to the search for new ways to evaluate their health. A new study by Scripps Institution of Oceanography at UC San Diego scientists has revealed that fluorescence, the dazzling but poorly understood light produced by corals, can be an effective tool for gauging their health. As ...

Pesticide application as potential source of noroviruses in fresh food supply chains

2013-03-12

Human norovirus (hNoV), also known as the winter vomiting bug, is one of the most common stomach bugs in the world. The virus is highly contagious, causing vomiting and diarrhea, and the number of affected cases is growing. Currently there is no cure; sufferers have to let the virus run its course for a few days. The consumption of fresh produce is frequently associated with outbreaks of hNoV but it remains difficult to identify where in the supply chain the virus first enters production. A new study, published in the International Journal of Food Microbiology investigated ...

Fertilizers could help tackle nutritional deficiency in African country, researchers say

2013-03-12

Enriching crops by adding a naturally-occurring soil mineral to fertilisers could potentially help to reduce disease and premature death in the African country of Malawi, researchers have said. An international study led by academics at The University of Nottingham has shown that dietary deficiency of the mineral selenium — which plays a vital role in keeping the immune system healthy and fighting illness — is likely to be endemic among the Malawi population. They found that most Malawi soils cannot supply enough selenium for adequate human nutrition and, in a paper ...

Friend or foe: Babies choose sides early

2013-03-12

Babies have a dark side under their cute exteriors, according to University of British Columbia-led study that finds infants as young as nine months embrace those who pick on individuals who are different from them. While previous research has shown that babies generally prefer kind actors, the new study – published by the Association for Psychological Science – is the first to suggest that infants condone antisocial behavior when it is directed at individuals who are dissimilar. "Our research shows that by nine months, babies are busy assessing their surroundings, ...

Babies prefer individuals who harm those that aren't like them

2013-03-12

Infants as young as nine months old prefer individuals who are nice to people like them and mean to people who aren't like them, according to a new study published in Psychological Science, a journal of the Association for Psychological Science. In our social lives, we tend to gravitate toward people who have things in common with us, whether it's growing up in the same town, disliking the same foods, or even sharing the same birthday. And research suggests that babies evaluate people in much the same way, preferring people who like the same foods, clothes, and toys that ...

Erectile dysfunction drug fails for diastolic heart failure patients

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: